Fly News Breaks for March 12, 2015
ACAD
Mar 12, 2015 | 08:25 EDT
After ACADIA announced that it would delay submitting its NUPLAZID for the treatment of Parkinson�s disease psychosis until 2H15, JMP Securities continues to view the drug as a high-quality asset with scarcity value. The firm keeps an Outperform rating on the stock.
News For ACAD From the Last 2 Days